Record Q1 Revenue and EPS Beat
Total Q1 revenue of $4.151 billion, up 8.4% year over year (6.0% at constant currency); adjusted diluted EPS of $2.90, up 7.4% year over year, both exceeding the high end of guidance.
Segment Revenue Strength
Commercial Solutions revenue of $1.754 billion, up 11.6% reported (8.5% constant currency); R&D Solutions revenue of $2.397 billion, up 6.2% reported (4.2% constant currency).
Adjusted EBITDA and Profitability
Adjusted EBITDA of $932 million, up 5.5% year over year; adjusted net income of $492 million; free cash flow of $491 million (100% of adjusted net income), a 15% increase year over year.
Strong Bookings and Backlog
R&D Solutions net new bookings of $2.5 billion, a double-digit increase year over year; total backlog of $34.2 billion (mid single-digit YoY growth) with $8.9 billion expected to convert to revenue in the next 12 months (high single-digit YoY growth).
Raised and Reaffirmed Guidance
Reaffirmed full-year 2026 revenue guidance of $17.15B–$17.35B (5.2%–6.4% growth) and adjusted EBITDA guidance of $4.05B–$4.25B; raised full-year adjusted diluted EPS guidance to $12.65–$12.95 (up 6.1%–8.6%).
Strong Q2 Outlook
Q2 guidance: revenue $4.28B–$4.34B (6.5%–8.0% YoY growth), adjusted EBITDA $955M–$975M (4.9%–7.1% YoY growth), adjusted diluted EPS $2.98–$3.08 (6.0%–9.6% YoY growth).
Material AI Progress and Adoption
Unveiled iqvia.ai and deployed 192 AI agents across 64 use cases; 19 of the top 20 pharma companies using IQVIA agents; AI cited as a driver of increased client demand and larger pipelines.
Notable Client Wins and Strategic Partnerships
Multiple multiyear and strategic wins: Pfizer regional promotion agreement (23 European countries), Boehringer Ingelheim global commercial intelligence collaboration (59 countries), top-five/top-10 pharma AI-enabled clinical and safety deals, partnership with Duke Clinical Research Institute in obesity; several EVP and patient analytics mandates.
Share Repurchase and Cash Position
Repurchased $552 million of shares in Q1; cash and cash equivalents $1.947 billion with approximately $1.2 billion of repurchase authorization remaining.
Acceleration in Organic Growth
Commercial Solutions organic growth accelerated to ~5% (roughly double last year) and R&D Solutions organic growth to ~3% (roughly triple last year), indicating improving underlying momentum.